Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial by Ying Cheng, Panpan Zhang, Ming Lu, Zhendong Chen, Lijie Song, Si Shi, Feng Ye, Xing Zhang, Baorui Liu, Dongmei Ji, Yanqiao Zhang, Weiguo Su, Michael Shi, Songhua Fan, Panfeng Tan, Chen Zhong

“…Here, we report the efficacy and safety of this combination regimen in treatment-naive advanced or metastatic non-small-cell lung cancer (NSCLC) patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1% or greater (PD-L1-positive) and patients with previously treated small-cell lung cancer (SCLC). Methods This open-label, single-arm phase II study included patients with treatment-naive advanced or metastatic PD-L1-positive NSCLC or previously treated SCLC in China. …”
Get full text

Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) by Joachim G J V Aerts, Sjoerd H van der Burg, Martijn P Lolkema, Sai Ping Lau, Freek R van ’t Land, Marjolein Y V Homs, Casper H J van Eijck

“…This study will determine the safety of DC/anti-CD40 agonistic antibody combination treatment, and treatment-induced tumour-specific immunological responses.Methods and analysis In this open-label, single-centre (Erasmus Univsersity Medical Center, Rotterdam, Netherlands), single-arm, phase I dose finding study, adult patients with metastatic pancreatic cancer with progressive disease after FOLFIRINOX chemotherapy will receive monocyte-derived DCs loaded with an allogeneic tumour lysate in conjunction with a CD40 agonistic antibody. …”
Get full text

Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in early breast cancer post-treatment follow-up (EMINENT): a single-centre, open-label, phase 2, parallel-group, pilot, randomised, controlled trialResearch in context by Raymond J. Chan, Fiona Crawford-Williams, Chad Yixian Han, Lee Jones, Alexandre Chan, Daniel McKavanagh, Marissa Ryan, Christine Carrington, Rebecca L. Packer, Megan Crichton, Nicolas H. Hart, Emma McKinnell, Melissa Gosper, Juanita Ryan, Bethany Crowe, Ria Joseph, Carolyn Ee, Jane Lee, Steven M. McPhail, Katharine Cuff, Laisa Teleni, Jon Emery

“…Methods: In this single-centre, open-label, phase II, pilot, randomised, controlled trial, individuals diagnosed with breast cancer (Stage 0–III) were randomised 1:1 to either usual care or intervention, which includes a 1) Specialist Nurse Consultation to co-develop a survivorship care plan (SCP), 2) Pharmacist Consultation, 3) Case Conference with General Practitioner (GP), and 4) shared follow-up care arrangements. …”
Get full text

Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma by Marshall Pitz, Eng-Siew Koh, Elizabeth H Barnes, Lucille Sebastian, Mandy L Ballinger, David M Thomas, Christopher O'Callaghan, John Simes, Hui K Gan, Sonia Yip, Hao-Wen Sim, Desma Spyridopoulos, Richard De Abreu Lourenco, Cynthia Hawkins, Kristen McParland, Benjamin Kong, Subotheni Thavaneswaran, Patrick J Wheeler

“…This study aims to improve outcomes by molecular profiling of patients at relapse, then matching them with the best available drug based on their molecular profile, maximising the chances of patient benefit while simultaneously testing multiple novel drugs.Methods and analysis Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2) will be an international, phase 2, multicentre, open-label, biomarker-directed, umbrella clinical trial for recurrent isocitrate dehydrogenase mutant, histologically grade 2/3 gliomas. …”
Get full text

Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial by Ling Wang, Xia Chen, Juan Zhao, Jiaxi Tang, Wanyan Tang, Bin Liao, Weiqi Nian

Get full text

HEMŞİRELER ARASINDA DAMGALAMA OLGUSU ÜZERİNE KEŞİFSEL BİR ÇALIŞMA by Ramazan Erdem, Sümeyye Özmen

Subjects: Get full text

Implicit Forms of Ethnic Insult for Europeans (as Found in Rhyming Slang) by E. Y. Gorshunova, Y. V. Gorshunov

Subjects: Get full text

Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trialResearch in context by Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Ludwig Fischer von Weikersthal, Karel Caca, Eray Goekkurt, Alexej Ballhausen, Greta Sommerhäuser, Annabel H.S. Alig, Swantje Held, Armin Jarosch, David Horst, Anke Reinacher-Schick, Stefan Kasper, Volker Heinemann, Sebastian Stintzing, Tanja Trarbach, Dominik P. Modest

“…Methods: In this final phase 2 trial analysis, adult mCRC patients responding to six cycles of FU/FA, oxaliplatin and panitumumab were randomized (1:1, open-label) to maintenance of either FU/FA + panitumumab or FU/FA alone. …”
Get full text

The grapevine ABC transporter B family member 15 is a trans-resveratrol transporter out of grapevine cells by Ascensión Martínez-Márquez, Ascensión Martínez-Márquez, Viviana Martins, Susana Sellés-Marchart, Susana Sellés-Marchart, Hernâni Gerós, Purificación Corchete, Roque Bru-Martínez, Roque Bru-Martínez, Roque Bru-Martínez

Subjects: Get full text

Associations between cerebral blood flow and progression of white matter hyperintensities by Siriluk Thammasart, Danielle J. Harvey, Pauline Maillard, Charles DeCarli, Corinne A. Donnay, Gregory J. Wheeler, Audrey P. Fan, Audrey P. Fan

Subjects: Get full text

Enhanced YOLOv10 Framework Featuring DPAM and DALSM for Real-Time Underwater Object Detection by Suthir Sriram, Aburvan P., Arun Kaarthic T. P., Nivethitha Vijayaraj, Thangavel Murugan

Subjects: Get full text

Association between carotid artery hemodynamics and neurovascular coupling in cerebral small vessel disease: an exploratory study by Peng Zeng, Bang Zeng, Xiaohua Wang, Feiyue Yin, Binglan Li, Lisha Nie, Lin Tian, Dan Luo, Yongmei Li

Subjects: “…multi-delay arterial spin labeling…”
Get full text

Farklı Şekilde Etiketlenen Likert Tipi Ölçeklerin Ölçme Değişmezliğine Etkisinin İncelenmesi by Meltem Yurtçu, Nuri Doğan, Ceylan Gündeğer

Subjects: Get full text

Pathway Of Low Anterior Resection syndrome (LARS) relief after Surgery (POLARiS): protocol for an international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort, with economic evaluation, process evaluation and qualitative sub-study, to explore the natural history of LARS and compare transanal irrigation and sacral neuromodulation to optimised conservative management for people with major LARS following a high or low anterior resection for colorectal cancer by Deborah D Stocken, Charles H Knowles, Jared Torkington, David Jayne, Julie Hepburn, Laura Knight, Neil Corrigan, Julie Cornish, Katie Gordon, Ashley Douglas, Kate Wilson, Megan Dale, Julie Croft, Christina Lloydwin, Alexandra Harriet Coxon-Meggy, Judith White, Alun Meggy, Aaron Quyn, Emily Farrow, Kheng-Seong Ng, Hannah Mather, Huey Yi Chong, Betty Tan, Ralph Powell, Andrea Warwick

“…Despite this, little is known about the natural history and there is poor evidence to support current treatment options.Methods and analysis The objectives of POLARiS are to explore the natural history of LARS and to evaluate the clinical and cost-effectiveness of transanal irrigation (TAI) or sacral neuromodulation (SNM) compared with optimised conservative management (OCM) for people with major LARS.POLARiS is a prospective, international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort design, with internal pilot phase, qualitative sub-study, process evaluation and economic evaluation. …”
Get full text

The interpretation and translation of Galatians 5:12 by D. F. Tolmie

“… As is evident from commentaries on Galatians and from various English translations, scholars do not agree on the meaning, rhetorical labelling and translation of the wish expressed by Paul in Galatians 5:12. …”
Get full text

Food-based indices for the assessment of nutritive value and environmental impact of meals and diets: A systematic review protocol. by Eva-Leanne Thomas, David Livingstone, Anne P Nugent, Jayne V Woodside, Paul Brereton

“…Though these challenges are multifaceted, shifting to healthy dietary choices from sustainable food systems is one solution. Food-based labelling is a common public-health strategy aimed at influencing consumption practices, primarily displaying front-of-pack nutrition labelling to encourage healthier choices. …”
Get full text

Da sociologia do desvio à criminologia crítica: os indígenas de Mato Grosso do Sul como outsiders by Igor Henrique da Silva Santelli, Antonio Guimarães Brito

“…In first part, it deals with the sociological approaches of Goffman, Becker and Elias, who point out the reasons and effects of stigmatization, labelling and marginalization and explain elementary fea- tures of the relationship between established people and outsiders. …”
Get full text

The “Problem” of L2 Writers in College Composition Placement: Identity, Outcomes, and the Future of Directed Self Placement by Vanessa Guida Mesina

“…Specifically, what are the implications of the identity labelling inherent in placing L2 students in courses designated as “ESL” or for “International Students” with regard to student investment and learning outcomes?  …”
Get full text

Synthesis and in vitro evaluation of spirobenzovesamicols as potential 11C-PET tracer alternatives to [18F]FEOBV for vesicular acetylcholine transporter (VAChT) imaging by Hugo Helbert, Winnie Deuther-Conrad, Michel de Haan, Barbara Wenzel, Gert Luurtsema, Wiktor Szymanski, Peter Brust, Rudi A. J. O. Dierckx, Ben L. Feringa, Philip H. Elsinga

“…Modern labelling techniques, in this case the [11C]MeLi cross-coupling methodology, expands labelling opportunities, allowing to explore novel vesamicol-based structures as potential PET-tracers. …”
Get full text

Gentzen and Temporal Sequents by Indrzejczak Andrzej

“…In both cases the main technical solution is the multiplication of the sorts of sequents and, additionally, the application of some kind of labelling to formulae. The first approach was proposed by Kaziemierz Trzęsicki at the 1980s. …”
Get full text